BioSpace News Archive

PMD Solutions Release: MEDICA Success for Respiratory Monitoring Leader

December 12, 2017

·

2 min read

Genetown

Acer Therapeutics Announces Proposed Underwritten Public Offering of Common Stock

Acer intends to grant the underwriters a 30-day option to purchase an additional 15% of the shares of common stock offered in the public offering.

December 12, 2017

·

4 min read

Drug Development

Actinium Pharmaceuticals Highlights Data at the American Society of Hematology Annual Meeting Showing CD33 Expression in a Significant Number of Multiple Myeloma Patients Supporting the Rationale for Actimab-M

Actinium is the first and only company thus far to have a CD33 targeted therapy for multiple myeloma and the results from this analysis provide further rationale for the Company’s myeloma initiative.

December 12, 2017

·

5 min read

argenx Announces Launch of Proposed Public Offering in the United States

Each of the ADSs offered in the Offering represents the right to receive one ordinary share, nominal value of €0.10 per share. All of the ADSs in the proposed Offering are to be sold by argenx.

December 12, 2017

·

6 min read

Drug Development

Agios’ Data From Phase I Studies of Ivosidenib or Enasidenib in Combination With Full Doses of Standard of Care Chemotherapy Demonstrate Tolerability and Preliminary Clinical Activity in Newly Diagnosed AML Patients With an IDH Mutation

The data were presented as part of the scientific program at the 59th American Society of Hematology Annual Meeting in Atlanta.

December 12, 2017

·

12 min read

Business

Scythian Biosciences Corp. Announces Appointment of Ottis Anderson to Pro Athlete Advisory Committee

The Company has also issued an additional 8,750 stock options with an exercise price of $8.65 per share for a period of five years, as well as 56,250 deferred share units to officers of the Company.

December 12, 2017

·

4 min read

Drug Development

Mustang Bio’s MB-102 (CD123 CAR) CAR T Therapy Achieves Complete Response in Acute Myeloid Leukemia and Blastic Plasmacytoid Dendritic Cell Neoplasm in Phase I Clinical Trial

The data were presented by City of Hope today in an oral session at the 59th American Society of Hematology (ASH) Annual Meeting.

December 12, 2017

·

8 min read

Drug Development

Fortress Biotech Announces Positive Clinical Data From Fortress Companies Presented at the 59th American Society of Hematology Annual Meeting

Columbia University reports Caelum Biosciences’ CAEL-101 was well tolerated, demonstrated early and clinically efficacious organ response in Phase 1a/1b trial in AL amyloidosis.

December 12, 2017

·

9 min read

VEXIM Announces the Results of the Simplified Tender Offer Initiated by Stryker

The public tender offer was opened from November 16, 2017, to December 6, 2017.

December 12, 2017

·

2 min read

Policy

Pluristem Granted Manufacturer Authorization and Good Manufacturing Practice (GMP) Certification by Israel’s Ministry of Health, Supporting Pivotal-Stage Studies

The MOH approval is required for Pluristem to continue manufacturing its cell therapies for use in ongoing pivotal studies and will also facilitate readiness of manufacturing for marketing of Pluristem’s placental cell therapies worldwide.

December 12, 2017

·

4 min read